However, after a medium period of about 12 months, even patients subjected to second line treatment with osimertinib, develop resistance with various mechanisms, including EGFR SNV, MET and HER2 amplification, genetic fusions etc. Recently, a series of clinical trials led to the approval of first line treatment of EGFR-positive NSCLC patients with osimertinib [22, 23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.